11 December 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need and with a lack of treatment alternatives, announces key insights from its poster presentation at the prestigious, 65th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, San Diego. Read […]
Updated safety and clinical efficacy data presented at leading immuno-oncology conference Exploratory studies suggest roginolisib boosts antitumoral immunity, whilst simultaneously disrupting tumor survival mechanisms Data suggest the potential of radiomics to assess changes in lesions over time, adding value above RECIST (Response Evaluation Criteria in Solid Tumors) Geneva, Switzerland and Amsterdam, The Netherlands, 8 December […]
Non-clinical data demonstrate clear impact of immune modulating vaccines targeting IDO1 and PD-L1 on several tumoral immune escape mechanisms in the tumor microenvironment (TME) leading to enhanced anti-tumor effect NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology […]
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced encouraging preliminary data from the company’s Phase 2 basket trial of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) (IOB-022/KN-D38) at the ESMO Congress being held in Madrid from October 20-24, 2023. […]
Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Stephane Dalle, the top recruiting investigator of the ATLAS-IT-05 study, will give a poster presentation today at the ESMO 2023 Congress. ATLAS-IT-05 is a Phase II open label clinical trial with LTX-315 […]
